How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

139,340 results for

Physical Medicine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy

Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03450252 Recruitment Status : Recruiting First Posted : March 1

2018 Clinical Trials

22. Ionically Crosslinked Chitosan Membranes Used as Drug Carriers for Cancer Therapy Application Full Text available with Trip Pro

Ionically Crosslinked Chitosan Membranes Used as Drug Carriers for Cancer Therapy Application The aim of this paper was to prepare, by the freeze-drying method, ionically crosslinked chitosan membranes with different contents of pentasodium tripolyphosphate (TPP) and loaded with 1,4-naphthoquinone (NQ14) drug, in order to evaluate how the physical crosslinking affects NQ14 release from chitosan membranes for cancer therapy application. The membranes were characterized by Fourier transform (...) -linker and among all membranes prepared, such that one crosslinked with 0.3% of TPP may become a potential delivery system for releasing NQ14 drug for cancer therapy.

2018 Materials

23. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy Full Text available with Trip Pro

Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive malignancy with a five year survival rate of <5%. The aberrant expression of extracellular matrix (ECM) in the tumor stroma forms a compact physical barrier, which that leads to insufficient extravasation and penetration of nanosized therapies. To overcome the severe resistance of PDAC to conventional therapies (...) , a sequentially triggered nanoparticle (aptamer/cell-penetrating peptide-camptothecin prodrug, i.e., Apt/CPP-CPTD NPs) with tumor penetration and intelligent drug release profile is designed. An ECM component (tenescin-C) targeting aptamer (GBI-10) is modified onto stroma-permeable cell-penetrating peptide (CPP) for the in vivo CPP camouflage and PDAC-homing. In PDAC stroma, tenascin-C can detach GBI-10 from CPP and exposed CPP can facilitate further PDAC penetration and tumor cell endocytosis. After being

2018 Advanced Science

24. Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy Full Text available with Trip Pro

Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy Chronic venous disease (CVD) is a common pathology, with significant physical and psychological impacts for patients and high economic costs for national healthcare systems. Throughout the last decades, several risk factors for this condition have been identified, but only recently, have the roles of inflammation and endothelial dysfunction been properly assessed. Although still incompletely (...) to review these pathophysiological mechanisms and their implications regarding currently available venoactive drug therapies.

2018 International journal of molecular sciences

25. A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy - Full Text View - ClinicalTrials.gov Hide glossary (...) participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy Estimated Study Start Date : March 15, 2019 Estimated Primary Completion Date : January 8

2018 Clinical Trials

26. A Couple-based Antiretroviral Therapy Adherence Intervention for People Who Inject Drugs

A Couple-based Antiretroviral Therapy Adherence Intervention for People Who Inject Drugs A Couple-based Antiretroviral Therapy Adherence Intervention for People Who Inject Drugs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. A Couple-based Antiretroviral Therapy Adherence Intervention for People Who Inject Drugs The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03555396 Recruitment Status : Not yet recruiting First Posted

2018 Clinical Trials

27. Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model

Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model Estimated Study Start Date : January 1, 2019 Estimated Primary Completion Date : July 1, 2020 Estimated Study Completion Date : July 1, 2020 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention (...) Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2018 Clinical Trials

28. Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy

to make recommendations. Other: Pharmacogenomic Testing pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism Other Names: Pillcheck Geneyouin Placebo Comparator: Control Pharmacist optimizing antidepressant therapy based on standard of care Other: Pharmacist Standard of Care Pharmacist providing standard of care as per usual practice Outcome Measures Go to Primary Outcome Measures : Treatment Satisfaction with Medicines (...) of uncertainty over the value of personalized medicine, recent studies show promising approaches for incorporating pharmacogenetics (PGx) data into routine patient care in order to reduce medication issues due to genetic factors. Over the last decades, clinical PGx research has made significant progress in defining which genetic variations are important for influencing inter-patient variability in drug response. Evidence-based consensus therapeutic guidelines for multiple drug-gene pairs are available

2018 Clinical Trials

29. Interprofessional education: evaluation of a radiation therapy and medical physics student simulation workshop Full Text available with Trip Pro

Interprofessional education: evaluation of a radiation therapy and medical physics student simulation workshop Interprofessional education (IPE) involves two or more professions engaged in learning with, from and about each other. An initiative was undertaken to explore IPE for radiation therapy (RT) and medical physics (MP) students through a newly developed workshop based around simulated learning. The aims of this study were to explore RT and MP students' perceptions of working as part (...) strategies which may enrich future professional collaboration.© 2018 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.

2018 Journal of medical radiation sciences

30. Antipsychotic therapy after failure with first-line treatment, should we increase the dose, switch drugs, or combine antipsychotics?

, or combine antipsychotics? Before opting for pharmacological management for patients with schizophrenia, psychotherapy and the prescription of physical exercise should be considered. If there is no improvement then medication could be indicated. When the initial medication fails, the first step would be to increase the medication up to the maximum dose; if not effective, the drug could be replaced by another antipsychotic agent, and if this fails, then clozapine should be considered. In cases (...) Antipsychotic therapy after failure with first-line treatment, should we increase the dose, switch drugs, or combine antipsychotics? Vol 20. DTB: Vol 20, No 5: October - December 2012 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 20, No 5: October - December 2012 DTB: Vol 20, No 5: October - December 2012 Content tools Share it Antipsychotic therapy after failure with first-line treatment: should we increase the dose, switch drugs

2013 Drug and Therapeutics Bulletin of Navarre (Spain)

31. Survey of medical students’ attitude and knowledge toward physical medicine and rehabilitation in Isfahan University of Medical Sciences Full Text available with Trip Pro

Survey of medical students’ attitude and knowledge toward physical medicine and rehabilitation in Isfahan University of Medical Sciences Physical medicine and rehabilitation (PMR) is a specialized clinical field of musculoskeletal diseases and physical impairment that is unknown for most of the medical students.This study aimed to assess medical students' attitude and knowledge toward PMR and its role in the diagnosis and treatment of musculoskeletal diseases.This cross-sectional study (...) was done on 175 medical students of Isfahan University of Medical Sciences from 2015 to 2016. Sample population was selected by random sampling among 350 students.Participants were evaluated by a research-made questionnaire with confirmed validity and reliability. This questionnaire included 36 questions divided in four parts including demographic data, knowledge, attitude, and performance ranking.Data were analyzed using SPSS 20. Statistical test for quantitative and qualitative variables was carried

2018 Journal of education and health promotion

32. A comparison of the real world effectiveness of catheter ablation and drug therapy in atrial fibrillation patients in a Chinese setting. Full Text available with Trip Pro

A comparison of the real world effectiveness of catheter ablation and drug therapy in atrial fibrillation patients in a Chinese setting. Studies have demonstrated that catheter ablation of atrial fibrillation is associated with better rhythm control than drug therapy. The present study aimed to assess the clinical outcomes and health-related quality of life of ablation therapy in a real world setting.A prospective, non-randomized, single center study in a real-world clinical setting in China (...) was conducted. Patients were followed up at 3, 6, and 9 months after baseline encounter. Propensity score matched patients receiving ablation or anti-arrhythmic drug therapy were compared. Incidence rate of atrial fibrillation recurrence and quality of life outcomes were measured and analyzed using log-rank test, multivariate logistic regression and mixed-effects linear regression respectively.In this study, 151 atrial fibrillation patients treated by ablation therapy and 318 patients treated by anti

2017 BMC Cardiovascular Disorders

33. Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

: Cohort Time Perspective: Other Official Title: PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure Actual Study Start Date : March 5, 2018 Estimated Primary Completion Date : June 17, 2019 Estimated Study Completion Date : July 1, 2019 Resource links provided by the National Library of Medicine related topics: available for: Groups and Cohorts Go to Group/Cohort Intervention/treatment Sacubitril/Valsartan (...) Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2017 Clinical Trials

34. 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice Full Text available with Trip Pro

5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice The targeting of 5-aminosalicylic acid (5-ASA), a first-line therapeutic agent for mild to moderate active ulcerative colitis (UC), to the site of inflammation has remained a challenge and an unmet requirement in the treatment of UC. However, nanoscale carriers for targeted drug delivery are promising for pharmacotherapy, and nanoparticles improve the pharmacokinetics of the loaded (...) therapeutics based on their physical properties. To design and prepare 5‑ASA‑loaded silicon dioxide nanoparticles (5‑ASA‑SiO2 NPs), a micro‑emulsion method was conducted, and their respective therapeutic effects were validated in a mouse model of UC. Cytotoxicity of 5‑ASA‑SiO2 NPs was detected in vitro using the Cell Counting Kit‑8 method. The therapeutic effect of 5‑ASA‑SiO2 NPs was assessed based on their disease activity index (DAI), colon histopathology, myeloperoxidase (MPO) and levels of tumor

2017 Molecular medicine reports

35. 3-D Bioprinting of Neural Tissue for Applications in Cell Therapy and Drug Screening Full Text available with Trip Pro

3-D Bioprinting of Neural Tissue for Applications in Cell Therapy and Drug Screening Neurodegenerative diseases affect millions of individuals in North America and cost the health-care industry billions of dollars for treatment. Current treatment options for degenerative diseases focus on physical rehabilitation or drug therapies, which temporarily mask the effects of cell damage, but quickly lose their efficacy. Cell therapies for the central nervous system remain an untapped market due (...) to the complexity involved in growing neural tissues, controlling their differentiation, and protecting them from the hostile environment they meet upon implantation. Designing tissue constructs for the discovery of better drug treatments are also limited due to the resolution needed for an accurate cellular representation of the brain, in addition to being expensive and difficult to translate to biocompatible materials. 3-D printing offers a streamlined solution for engineering brain tissue for drug discovery

2017 Frontiers in bioengineering and biotechnology

36. Comparison of the Effects of Transcutaneous Electrical Nerve Stimulation and Low-Level Laser Therapy on Drug-Resistant Temporomandibular Disorders Full Text available with Trip Pro

Comparison of the Effects of Transcutaneous Electrical Nerve Stimulation and Low-Level Laser Therapy on Drug-Resistant Temporomandibular Disorders Temporomandibular disorder (TMD) is a clinical term used for clinical signs and symptoms that affect the temporomandibular joints, masticatory muscles, and associated structures. Surgical and non-surgical treatments can be used for management of TMD. Non-surgical route is the main part of the treatment, since clinicians prefer non-aggressive (...) treatment for TMD such as pharmacological and physical therapy. Low-level laser therapy (LLLT) and transcutaneous electrical nerve stimulation (TENS) are the main procedures in physical therapy.The aim of this study was to evaluate the effectiveness of TENS and LLLT in treatment of TMD patients who did not respond to pharmacological therapy.This clinical trial was performed on 45 patients who randomly received either TENS or LLLT for 8 sessions. LLLT was applied with diode laser (Ga-Al-As, 980nm, dose

2017 Journal of dentistry Controlled trial quality: uncertain

37. Experiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services Full Text available with Trip Pro

Experiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services Despite significant advancements in new treatment modalities for rheumatoid arthritis with biological therapies, foot complications remain a disabling and common feature of the disease. In this study the aim was to explore and describe the personal experiences of people with rheumatoid arthritis in receipt of biologic treatments in a bid to understand (...) the impact of this form of medication on their mobility.An interpretative phenomenological analysis (IPA) was undertaken to explore in depth the individual experience of rheumatoid disease through personal accounts of the patient journey spanning both 'before' and 'after' the instigation of biologic therapy. A purposive sampling strategy was adopted and in-depth semi structured interviews used to facilitate rich, detailed interview data exploring the lived experiences of individuals undertaking

2017 Journal of foot and ankle research

38. A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-admin

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-admin A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual (...) the PK of the study drugs. Additionally, any GI surgery (e.g., partial gastrectomy, pyloroplasty) including cholecystectomy that may impact drug absorption. Any major surgery, as determined by the investigator, within 4 weeks of first IMP dosing. Donation of > 400 mL of blood within 8 weeks or donation of plasma (except at the Screening Visit) within 4 weeks of first IMP dosing. Blood transfusion within 4 weeks of first IMP dosing. Inability to tolerate oral medication. Inability to tolerate

2017 Clinical Trials

39. Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs. Full Text available with Trip Pro

Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs. To assess the effectiveness of a cognitive-behavioral therapy-based intervention (Superwellness Program) on weight gain compared with a treatment-as-usual (TAU) approach in patients treated with antipsychotics, and to evaluate the relationship between body mass index (BMI) variation and clinical variables.Eighty-five patients treated (...) with antipsychotics were allocated across two groups, experimental (n=59) and control (n=26). The Superwellness Program (experimental group) consisted of 32 twice-weekly 1-hour sessions, conducted by a psychologist and a nutritionist/nurse, concurrently with moderate food intake and moderate physical activity plans. Sociodemographic, clinical, and biological variables were collected at baseline, at the end of intervention (16 weeks), and after 6 months.BMI change from baseline differed significantly between

2017 Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

40. Responsible use of high-risk medical devices: the example of 3D printed medical devices

AIMDD Active Implantable medical device Directive ATMP BCIP BOIP BFM advanced therapy medicinal product Benelux Convention on Intellectual Property Benelux Office for intellectual property Budget of Financial Means CAD computer-aided design CBA cost-benefit analyses CC Civil Code CCA cost-consequence analyses CEA CI cost-effectiveness analyses confidence interval CMA cost-minimization analyses CPD CRD College physicians-directors Centre for Review and Dissemination CUA cost-utility analyses CPC (...) EUDAMED European Databank on Medical Devices EUIPO EUnetHTA European Union Intellectual Property Office European Network for Health Technology Assessment EUTM DD DMCA FAMHP European Union Trade Mark Directive on the legal protection of designs Digital Millennium Copyright Act Federal Agency for Medicines and Health Products (FAGG-AFMPS) FDA Food and Drug Administration GDPR General Data Protection Regulation HSR HTA Health Services Research Health Technology Assessment IC IDEAL INAHTA Insurance

2018 Belgian Health Care Knowledge Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>